Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bite Clear all
Completed Phase 2 Interventional

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

NCT05532735
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ANXV
Biological
Lead sponsor
Annexin Pharmaceuticals AB
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 21, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 21, 2026, 5:22 PM EDT
Terminated Phase 4 Interventional

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

NCT04563299
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-Adhesive

NCT05173974
View directory record Official record
Conditions
Denture Retention
Interventions
Super Poligrip Free, Experimental Denture Adhesive 1, Experimental Denture Adhesive 2
Device
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device

NCT05136417
View directory record Official record
Conditions
Left Atrial Appendage Occlusion
Interventions
intra-procedural intracardiac echocardiography (ICE) probe
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Santa Monica, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 21, 2026, 5:22 PM EDT
Active, not recruiting Phase 1 Interventional

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

NCT01736059
View directory record Official record
Conditions
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
Interventions
CD34+ bone marrow stem cells intravitreal
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
View directory record Official record
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 5:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Comparing TR Band to Statseal in Conjunction With TR Band

NCT03028025
View directory record Official record
Conditions
Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-Induced Bleeding, Coronary Artery Disease
Interventions
StatSeal, TR Band
Device
Lead sponsor
VA Long Beach Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
View directory record Official record
Conditions
Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
Interventions
VP-102 Cantharidin, topical film forming solution
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

NCT00624078
View directory record Official record
Conditions
Scorpion Sting Envenomation
Interventions
Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Drug
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
Not listed
Enrollment
1,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Casa Grande, Arizona • Chandler, Arizona • Douglas, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional

Tracheal Occlusion To Accelerate Lung Growth (TOTAL) Trial for Severe Pulmonary Hypoplasia

NCT01240057
View directory record Official record
Conditions
Congenital Diseases, Diaphragmatic Hernia, Pulmonary Hypoplasia
Interventions
fetal endoluminal tracheal occlusion, watchful waiting during pregnancy
Procedure · Other
Lead sponsor
University Hospital, Gasthuisberg
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Bite Counter

NCT02763358
View directory record Official record
Conditions
Weight Loss
Interventions
Bite Counter
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tick-borne Illness and Clothing Study of Rhode Island

NCT02613585
View directory record Official record
Conditions
Tick Bites, Tick-borne Diseases
Interventions
Permethrin Impregnated Clothing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting No phase listed Observational

PROMISE Registry: PROspective Study on Management of Ischemic Stroke Secondary to mEvo Registry

NCT07746947
View directory record Official record
Conditions
Management of Ischemic Stroke, Medium Vessel Occlusion
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional

Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study

NCT07620262
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Remapping Procedure
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bay Shore, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stroke Feasibility Study

NCT01997905
View directory record Official record
Conditions
Atrial Fibrillation, AFib
Interventions
AtriClip LAA Exclusion Device
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 5:22 PM EDT
Completed No phase listed Observational

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

NCT05791695
View directory record Official record
Conditions
Intraocular Inflammation, Suspected Endophthalmitis
Interventions
Non Applicable
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery

NCT02085551
View directory record Official record
Conditions
Peripheral Arterial Occlusion or Emboli
Interventions
Mechanical Thrombectomy by the Indigo System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 21, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

NCT01802073
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Oral Vancomycin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 21, 2026, 5:22 PM EDT